Gratzke C, Chapple C, Mueller ER, et al. - A literature search was carried out in June 2018 in order to assess the efficiency and safety of combination therapy in individuals with overactive bladder (OAB). Publications reported on clinical efficiency, safety, and health-associated quality of life (HRQoL) for mirabegron (M) plus solifenacin (S) from three 12-wk randomized controlled trials (RCTs)—SYMPHONY, SYNERGY, and BESIDE—and a 12-mo RCT, SYNERGY II. For individuals with OAB, mirabegron plus solifenacin gave efficient as well as well-endured treatment. Moreover, limited data for dual antimuscarinic therapy recommend an advantage in individuals with moderate-to-severe symptoms.